- United Kingdom
- /
- Biotech
- /
- AIM:ABC
Abcam plc (LON:ABC): Will The Growth Last?
Based on Abcam plc's (LON:ABC) earnings update on 30 June 2019, analysts seem fairly confident, with earnings expected to grow by 34% in the upcoming year against the past 5-year average growth rate of 12%. By 2020, we can expect Abcam’s bottom line to reach UK£60m, a jump from the current trailing-twelve-month of UK£45m. I will provide a brief commentary around the figures and analyst expectations in the near term. Readers that are interested in understanding the company beyond these figures should research its fundamentals here.
View our latest analysis for Abcam
How is Abcam going to perform in the near future?
The 8 analysts covering ABC view its longer term outlook with a positive sentiment. Given that it becomes hard to forecast far into the future, broker analysts tend to project ahead roughly three years. To get an idea of the overall earnings growth trend for ABC, I’ve plotted out each year’s earnings expectations and inserted a line of best fit to determine an annual rate of growth from the slope of this line.
From the current net income level of UK£45m and the final forecast of UK£81m by 2022, the annual rate of growth for ABC’s earnings is 16%. EPS reaches £0.38 in the final year of forecast compared to the current £0.22 EPS today. Margins are currently sitting at 17%, which is expected to expand to 23% by 2022.
Next Steps:
Future outlook is only one aspect when you're building an investment case for a stock. For Abcam, I've put together three essential factors you should further research:
- Valuation: What is Abcam worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether Abcam is currently mispriced by the market.
- Future Earnings: How does Abcam's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High-Growth Alternatives : Are there other high-growth stocks you could be holding instead of Abcam? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.
A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it.

Any moat with an opt-out clause for your competitors is just a fence around your own garden.
Worth looking at what previous legal action actually did to Meta rather than reaching for tobacco. The FTC's record five billion dollar privacy fine in 2019 was met with the stock rising, because it came in below fears and removed an open question. GDPR was designed to constrain large platforms and increased their share of the European ad market, because compliance cost fell hardest on small intermediaries. The FTC's antitrust case, the one that could genuinely have broken the company up, was decided in Meta's favour last November. The only thing that ever meaningfully hurt the business was Apple changing a tracking default, and Meta out-spent that too, while the ad-tech firms that could not afford to rebuild disappeared. The pattern is not that Meta survives regulation. It is that regulation keeps costing its smaller competitors more.
Andrew LeggetGreat earnings season, but are the earnings real?

About AIM:ABC
Abcam
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery.
Excellent balance sheet and good value.